Cyclobenzaprine: Proper Usage and Precautions
Cyclobenzaprine should be prescribed at 5 mg three times daily for most patients, with the option to increase to 10 mg three times daily based on individual response, and should not be used for longer than 2-3 weeks due to risk of dependence and adverse effects. 1
Dosage and Administration
- Standard dosage is 5 mg three times daily, which may be increased to 10 mg three times daily if needed 1
- Lower dosing (5 mg) should be considered for elderly patients and those with hepatic impairment 1
- Extended-release formulation (30 mg once daily) provides comparable systemic exposure to immediate-release (10 mg three times daily) with a more consistent concentration-time profile 2, 3
- Treatment duration should not exceed 2-3 weeks as longer use is not recommended 1
- If discontinuing after long-term use, implement a gradual taper over 2-3 weeks to prevent withdrawal symptoms including malaise, nausea, and headache 4, 5
Mechanism and Clinical Uses
- Cyclobenzaprine is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants 5, 4
- Primarily indicated for relief of muscle spasm associated with acute, painful musculoskeletal conditions 6, 7
- Has shown efficacy in fibromyalgia management, though with only a weak recommendation (75% expert agreement) 5
- 5 mg TID has demonstrated similar efficacy to 10 mg TID with lower incidence of sedation 6
Precautions and Contraindications
Use with caution in patients with:
Contraindicated with:
Adverse Effects
Most common adverse effects include:
Potential for drug interactions:
Special Considerations
- Hold cyclobenzaprine on the day of surgery due to potential interactions with anesthetics and sedatives 5
- Cyclobenzaprine may impair mental/physical abilities required for operating machinery or driving 1
- The American Geriatrics Society Beers Criteria® identifies muscle relaxants including cyclobenzaprine as potentially inappropriate medications for older adults due to anticholinergic effects and sedation 5
- In patients with fibromyalgia, cyclobenzaprine may be considered but has only moderate evidence quality 5
Patient Education
- Advise patients about sedative effects and to avoid alcohol and other CNS depressants while taking cyclobenzaprine 1
- Inform patients about anticholinergic side effects to monitor for (dry mouth, constipation, urinary retention) 4, 1
- Warn patients about the risk of serotonin syndrome when combined with other serotonergic medications 1
- Instruct patients not to abruptly discontinue medication after prolonged use 4, 5